Contributor Since 2012
Innovation And Extensive Patent Portfolio Make ARRAYIT Future Look Bright
Arrayit Corporation (ARYC) leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure.
The global healthcare industry is witnessing a paradigm shift, skewed towards point-of-care diagnostics, cost-effective treatment modalities, and personalized medicine, which not only offers efficient early diagnosis, but also treats cancer conditions in order to reduce the healthcare cost and disease burden. Cancer/Tumor profiling is one such technology with the exact potential to revolutionize cancer diagnostics and therapeutics in the healthcare industry.
Genetic testing has potential benefits whether the results are positive or negative for a gene mutation. Test results can provide a sense of relief from uncertainty and help people make informed decisions about managing their health care. For example, a negative result can eliminate the need for unnecessary checkups and screening tests in some cases. A positive result can direct a person toward available prevention, monitoring, and treatment options. Some test results can also help people make decisions about having children. Newborn screening can identify genetic disorders early in life so treatment can be started as early as possible. The physical risks associated with most genetic tests are very small, particularly for those tests that require only a blood sample or cheek smear.
In Arrayit's microarray technology, 100,000 individual patient samples can be placed on a single microarray substrate slide and then immersed in a solution that contains known markers for specific diseases. The results are evaluated based on the signals - red spots confirm the presence of the disease and green spot show a lack of a particular disease. This simpler unique cutting edge technology can be used to study both genetic variations and biological functions in a larger scale.
Genome testing is hovering around $1000 more or less which limits the field of patients opting for the testing but for those patients with known family history of serious disease it is many times a necessary test. The innovation of 100,000 tests on a slide and a little creativity in the sample preparation source plate, the time is reduced from eight hours to two hours
Practical uses of this technology. Imagine sitting in your Doctor's office with a headache on one side of your head. Migraine, sinus infection, stroke, cold or flu all the same symptoms? The nurse swabs inside your cheek or pricks your finger for a blood sample and places it on a slide. In less than 20 minutes the results. This is not a genome evaluation but a smaller scale diagnosis. Today many similar tests take 14 or more days for results. Hope it wasn't a stroke.
Arrayit is developing a ovarian cancer monitoring and screening diagnostic test, As of now there are no approved ovarian cancer tests, an approval could lead to a profitable new line of diagnostic
Who are the customers? Arrayit has a worldwide marketing platform with sales in many countries. Research labs are always looking for the best technology with reliability a main concern. The Grandaddy of all biotech Genentech purchased Arrayit's NanoPrint™ LM60 Microarrayer Platform including a manufacturing robot.
Steve Jobs would be proud of the marketing and placing of products and services in colleges and universities. Jobs invented the idea of selling to schools and giving teachers a discount on their products. Every student in Apple schools learned on Apple and most are now loyal customers. How many people drive the brand of car they learned to drive in?
Why I like ARRAYIT
ARRAYIT is poised for explosive growth and premium evaluation starting in 2014
The view from where I am sitting sees this undervalued stock with a bright future. The patent portfolio of intellectual property alone should be worth in the neighborhood of $100 million.
Revenue reported 3rd quarter 2013 10Q shows an increase over the same three months a year earlier of 51 percent with profitability and a $1.48M net income improvement over 2012 for the first nine months of this year. The nine month comparison show a 28 percent increase. This business is moving forward. Market Watch lists P/E ratio of 7.42 with EPS at .05
My personal interest was tweaked when ARYC popped up on a technical market scan that I do weekly. Usually looking at mid-cap stocks however the technology and business plan is so compelling especially with the next generation of healthcare. The marketing efforts are paying off especially the Arrayit Amazon.com store that offers easy worldwide access to products and services offered 24 hours a day. Imagine the sales department opening their Amazon account being greeted on Monday morning with a $100,000 order. The "Affordable Care Act" has a greater focus on testing and preventing disease and that's the business ARYC is transforming.
Anybody else interested ?
Recent inquires are pretty impressive for a small cap stock and dispel the myth of Wall Street not interested in sub-five buck stocks.
Analyst calls and coverage in Jan 2014 pretty impressive group I would say.
Murphy Analytics initiated coverage
Goldman Opportunity Research report
Recent offering participants include a partnership that includes the legendary Dr. Mark Frost who is well followed on the street.
This report was prepared using public information from various sources including but not limited to SEC documents, Arrayit Co. reports, newsletters, conference calls and documents pertaining to competing companies.